Show simple item record

dc.rights.licenseCC-BY-NC-ND
dc.contributorFloor Lubberman, Emmy Boerrigter, Arnold Baars
dc.contributor.advisorEgberts, A.C.G.
dc.contributor.authorMurdoch, Indy
dc.date.accessioned2023-12-31T01:00:55Z
dc.date.available2023-12-31T01:00:55Z
dc.date.issued2023
dc.identifier.urihttps://studenttheses.uu.nl/handle/20.500.12932/45687
dc.description.abstractMethods. In this retrospective observational cohort-study, patients were divided in a fasted-group and fed-group. Progression free survival and overall survival were compared between the two groups, using Kaplan-Meier analysis with log-rank test. Toxicity was measured as incidence of side-effects. Results. 26 patients were included in the fed-group and 72 patients were included in the fasted-group. The fed-group had a median progression free survival of 315 days (IQR 154-436 days), the fasted-group had a median progression free survival of 230 days (IQR 140-431 days). Patients who were diagnosed with gleason score 8 and had received prior docetaxel treatment had a median progression free survival of 315 days (IQR 210-723 days) in the fed-group and 155 days (IQR 82-288 days)in the fasted group. Median overall survival was not reached for the fed-group. Toxicity risk was similar in both groups. Interpretation. Concomitant intake of AA with food does not lead to prolonged survival. However, patients who were diagnosed with gleason score 8 or higher and had prior chemotherapy saw a modest, non-significant, improvement in progression free survival. These results demonstrate that it is feasible to investigate the food effect in specific patient populations in a larger randomized prospective study, and is therefore recommended.
dc.description.sponsorshipUtrecht University
dc.language.isoEN
dc.subjectAbiraterone Acetate (AA) significantly improves progression free survival and overall survival in patients with metastatic castration resistant prostate cancer (mCRPC). AA is taken in a fasted state, according to the drug label, as intake with food significantly increases exposure. We sought to demonstrate if concomitant intake of AA with food would result in prolonged progression free survival in mCRPC patients, while at the same time does not lead to increased toxicity.
dc.titleAbiraterone with or without Food? A Retrospective pilot study On Determining the effect of abiraterone Intake with food on Toxicity and life-Expectancy in mCRPC patients
dc.type.contentMaster Thesis
dc.rights.accessrightsOpen Access
dc.subject.courseuuFarmacie
dc.thesis.id8860


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record